Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation

American Journal of Hematology

Volumn 90, Issue 7, 2015, Pages 624-628

  Esrick, Erica B ^a,b   Mcconkey, Marie ^c   Lin, Katherine ^c   Frisbee, Alyse ^c   Ebert, Benjamin L ^b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTINOSTAT; HEMOGLOBIN GAMMA CHAIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HYDROXYUREA; SHORT HAIRPIN RNA; HDAC1 PROTEIN, HUMAN; HDAC2 PROTEIN, HUMAN; HEMOGLOBIN BETA CHAIN; SMALL INTERFERING RNA;

ARTICLE; CD34 SELECTION; CELL CYCLE PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INACTIVATION; ERYTHROID PRECURSOR CELL; GENE; GENE SILENCING; HDAC1 GENE; HDAC2 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGONISTS; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CELL CYCLE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION; GENE VECTOR; GENETICS; LENTIVIRINAE; METABOLISM; PRIMARY CELL CULTURE;

BETA-GLOBINS; BONE MARROW CELLS; CELL CYCLE; CELL DIFFERENTIATION; GAMMA-GLOBINS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HUMANS; HYDROXYUREA; LENTIVIRUS; PRIMARY CELL CULTURE; RNA, SMALL INTERFERING;

EID: 84931956276     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24019     Document Type: Article

References (31)

1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376:2018-2031.
2. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am 2010;24:199-214.
3. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762-769.
4. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984;74:652-656.
5. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995;332:1317-1322.
6. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. J Am Med Assoc 2003;289:1645-1651.
7. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010;85:403-408.
8. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS). Blood 2010;115:2354-2363.
9. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric hydroxyurea group. Blood 1999;94:1550-1554.
10. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97:3628-3632.
11. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103:2039-2045.
12. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002;99:10-14.
13. DeSimone J, Heller P, Hall L, et al. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci U S A 1982;79:4428-4431.
14. Ley TJ, DeSimone J, Anagnou NP, et al. 5-Azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med 1982;307:1469-1475.
15. DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002;99:3905-3908.
16. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993;328:81-86.
17. Liakopoulou E, Blau CA, Li Q, et al. Stimulation of fetal hemoglobin production by short chain fatty acids. Blood 1995;86:3227-3235.
18. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999;93:1790-1797.
19. Cao H, Stamatoyannopoulos G, Jung M. Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood 2004;103:701-709.
20. Cao H, Stamatoyannopoulos G. Histone deacetylase inhibitor fk228 is a potent inducer of human fetal hemoglobin. Am J Hematol 2006;81:981-983.
21. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994;84:339-343.
22. Reid ME, El Beshlawy A, Inati A, et al. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2, 2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol 2014;89:709-713.
23. Bradner JE, Mak R, Tanguturi SK, et al. Chemical genetic strategy identifies histone deacetylase 1 (hdac1) and hdac2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A 2010;107:12617-12622.
24. Sowa Y, Orita T, Hiranabe-Minamikawa S, et al. Histone deacetylase inhibitor activates the p21/waf1/cip1 gene promoter through the sp1 sites. Ann N Y Acad Sci 1999;886:195-199.
25. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000;97:10014-10019.
26. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: Can we interpret the code? Mol Oncol 2012;6:637-656.
27. Moffat J, Grueneberg DA, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006;124:1283-1298.
28. Dampier C, LeBeau P, Rhee S, et al. Health-related quality of life in adults with sickle cell disease (SCD): A report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol 2011;86:203-205.
29. Panepinto JA, O'Mahar KM, DeBaun MR, et al. Health-related quality of life in children with sickle cell disease: Child and parent perception. Br J Haematol 2005;130:437-444.
30. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663-1672.
31. Ware RE, Helms RW; Investigators SW. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood 2012;119:3925-3932.